LIFE - aTyr Pharma, Inc.
| Previous Close | 0.5401 |
| Open | 0.5340 |
| Bid | 0.5340 x 1000 |
| Ask | 0.5550 x 900 |
| Day's Range | 0.5340 - 0.5597 |
| 52 Week Range | 0.3750 - 2.6000 |
| Volume | 7,248 |
| Avg. Volume | 394,880 |
| Market Cap | 19.257M |
| Beta (3Y Monthly) | 2.02 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.1520 |
| Earnings Date | Aug 13, 2018 - Aug 17, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 0.75 |
- GlobeNewswire•2 days ago
aTyr Pharma to Host Inaugural Summit Meeting on Neuropilin-2 (NRP-2) Biology
SAN DIEGO, April 16, 2019 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced that the Company will host a summit meeting on Neuropilin-2 (NRP-2) biology on April 17, 2019 in San Diego. This one-day summit meeting will bring together key researchers from across the United States to discuss the most recent discoveries relating to the development of therapeutics directed to the NRP-2 co-receptor, and related signaling pathways. “We are pleased to host this inaugural summit meeting which should serve to advance our collective understanding of the emerging role of NRP-2 in modulating immune responses across a broad range of disease states,” said Dr. Sanjay Shukla, President and Chief Executive Officer of aTyr.
- GlobeNewswire•7 days ago
aTyr Pharma Announces $5 Million Registered Direct Offering led by The Federated Kaufmann Small Cap Fund
SAN DIEGO, April 11, 2019 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced that it has entered into a definitive agreement with The Federated Kaufmann Small Cap Fund and Paul Schimmel, Ph.D., an existing stockholder and a director of the company, to purchase an aggregate of $5.0 million of aTyr’s common stock in a registered direct offering conducted without an underwriter or placement agent. Proceeds from the offering will be used to advance clinical development of aTyr’s lead therapeutic candidate, ATYR1923, and for other general corporate purposes. The securities described above are being offered pursuant to a shelf registration statement (File No. 333-211998) filed with the Securities and Exchange Commission (SEC), which was declared effective on June 22, 2016.
- Thomson Reuters StreetEvents•8 days ago
Edited Transcript of LIFE earnings conference call or presentation 25-Mar-19 9:00pm GMT
Q4 2018 aTyr Pharma Inc Earnings Call
- GlobeNewswire•10 days ago
aTyr Pharma to Present Poster at the American Thoracic Society 2019 International Conference
SAN DIEGO, April 08, 2019 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced that the Company will present an abstract in a poster presentation at the American Thoracic Society (ATS) 2019 International Conference, which is being held May 19-22 in Dallas. ”We are very pleased to present these compelling results at this year’s ATS conference, which highlight ATYR1923’s unique mechanism of action and demonstrate activity in a range of ILD models,” said Dr. Sanjay Shukla, President and Chief Executive Officer of aTyr. “Notably, ATYR1923 appears to show potent immunomodulatory effects in models of fibrosing ILD that are highly inflammatory or T cell driven.
- Zacks•21 days ago
Atyr Pharma (LIFE) Upgraded to Buy: Here's Why
Atyr Pharma (LIFE) has been upgraded to a Zacks Rank 2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
- Associated Press•24 days ago
Atyr Pharma: 4Q Earnings Snapshot
The San Diego-based company said it had a loss of 21 cents per share. For the year, the company reported that its loss narrowed to $34.5 million, or $1.15 per share. In the final minutes of trading on ...
- GlobeNewswire•24 days ago
aTyr Pharma Announces Fourth Quarter and Full Year 2018 Results and Provides Corporate Update
Phase 1b/2a proof-of-concept clinical trial of ATYR1923 in pulmonary sarcoidosis patients initiated in December 2018 First tRNA synthetase partnership announced in March.
- ACCESSWIRE•24 days ago
aTyr Pharma, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / March 25, 2019 / aTyr Pharma, Inc. (NASDAQ: LIFE ) will be discussing their earnings results in their 2018 Fourth Quarter Earnings to be held on March 25, 2019 at 5:00 PM Eastern ...
- GlobeNewswire•28 days ago
aTyr Pharma Announces Poster Presentation at the 2019 American Association for Cancer Research (AACR) Annual Meeting
SAN DIEGO, March 21, 2019 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced that data from its successful pilot study with the University of Nebraska Medical Center will be presented in an abstract at the 2019 AACR Annual Meeting, which is being held March 29 - April 3 at the Georgia World Conference Center in Atlanta. The poster may be accessed on the aTyr Pharma website at https://www.atyrpharma.com/our-science/publications/ following the presentation.
- GlobeNewswire•last month
aTyr Pharma to Announce Fourth Quarter and Full Year 2018 Financial Results on March 25th
SAN DIEGO, March 18, 2019 -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel.
- GlobeNewswire•last month
aTyr Pharma Announces Research Collaboration With Global Biotherapeutics Leader CSL Behring
SAN DIEGO, March 11, 2019 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced that it has entered into a research collaboration and option agreement with global biotherapeutics leader CSL Behring, for the development of product candidates derived from up to four tRNA synthetases from aTyr’s preclinical pipeline. “This research collaboration with CSL Behring, an industry leader in the development of plasma-derived and recombinant therapeutics for rare and serious diseases, represents an important validation of our science and enables us to accelerate development of potential IND candidates from our pipeline,” said Dr. Sanjay Shukla, President and Chief Executive Officer of aTyr.
- GlobeNewswire•last month
aTyr Pharma Announces Participation at March Investor Conferences
SAN DIEGO, March 04, 2019 -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel.
- GlobeNewswire•2 months ago
aTyr Pharma Presents Compelling Preclinical Data Highlighting Potential of ATYR1923 to Regulate Myeloid Cell Biology During Lung Inflammation
SAN DIEGO, Feb. 27, 2019 -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel.
- CNW Group•2 months ago
Evolve Announces February 2019 Distributions for Evolve ETFs
Evolve Announces February 2019 Distributions for Evolve ETFs
- GlobeNewswire•2 months ago
aTyr Pharma to Present at the BIO CEO & Investor Conference
SAN DIEGO, Feb. 05, 2019 -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel.
- GlobeNewswire•3 months ago
aTyr Pharma Announces Research Collaboration with the University of Nebraska Medical Center and Expansion of Successful Pilot Study
Collaboration to advance neuropilin-2 biology and explore potential therapeutic opportunities for ATYR1923 Reinforces aTyr’s commitment to working with a strategic network of.
- GlobeNewswire•3 months ago
Pangu BioPharma (an aTyr Pharma Subsidiary) and The Hong Kong University of Science and Technology Recognized for Pioneering Work Leading to New Investigational Therapeutic for Lung Disease
SAN DIEGO and HONG KONG, Jan. 16, 2019 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today recognized the collaboration between its Hong Kong subsidiary, Pangu BioPharma (Pangu), and The Hong Kong University of Science and Technology (HKUST) for contributions leading to the discovery of aTyr’s lead clinical candidate, ATYR1923, which is currently being evaluated in a Phase 1b/2a study in patients with pulmonary sarcoidosis.
- Zacks•3 months ago
Zacks.com featured highlights include: G-III, SP Plus, Penske Automotive, aTyr and Avinger
Zacks.com featured highlights include: G-III, SP Plus, Penske Automotive, aTyr and Avinger
- Zacks•3 months ago
What Bargain Hunting? Tap 5 Stocks With Rising P/E
Bet on these top-ranked stocks with rising P/E to realize outsized gains.
- GlobeNewswire•3 months ago
aTyr Pharma Announces Participation at Upcoming San Francisco Investor Events
SAN DIEGO, Jan. 02, 2019 -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel.
- Simply Wall St.•4 months ago
Need To Know: aTyr Pharma, Inc. (NASDAQ:LIFE) Insiders Have Been Buying Shares
We often see insiders buying up shares in companies that perform well over the long term. Unfortunately, there are also plenty of examples of share prices declining precipitously after insiders Read More...
- GlobeNewswire•4 months ago
aTyr Pharma Announces Initiation of Phase 1b/2a Study of ATYR1923 in Patients with Pulmonary Sarcoidosis and Collaboration with the Foundation for Sarcoidosis Research (FSR)
SAN DIEGO, Dec. 04, 2018 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced the initiation of a Phase 1b/2a study evaluating its lead candidate, ATYR1923, in patients with pulmonary sarcoidosis following acceptance of the Company’s investigational new drug application by the US Food and Drug Administration. Under the terms of the collaboration, FSR will assist with clinical trial site initiation and patient enrollment.
- Zacks•5 months ago
Zacks.com highlights: Asbury Automotive, OncoGenex Pharmaceuticals, aTyr Pharma, Avinger and Sunesis Pharmaceuticals
Zacks.com highlights: Asbury Automotive, OncoGenex Pharmaceuticals, aTyr Pharma, Avinger and Sunesis Pharmaceuticals
- GlobeNewswire•5 months ago
aTyr Pharma to Present at the BMO 2018 Prescriptions for Success Healthcare Conference
SAN DIEGO, Nov. 28, 2018 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced that Sanjay Shukla, M.D., M.S., president and chief executive officer, will present at the upcoming BMO 2018 Prescriptions for Success Healthcare Conference at the Mandarin Oriental in New York City on Wednesday, December 12, 2018, at 2:30 pm Eastern Time.
- Zacks•5 months ago
5 Top-Ranked Rising P/E Stocks to Lure Investors
Inside the top-ranked stocks that have been exhibiting rising P/E ratios.
